Biozenta Lifescience Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Biozenta Lifescience Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $113.9K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Biozenta Lifescience Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $113.9K Trade | TransData Nexus

Biozenta Lifescience Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $113.9K Total Trade · DGFT Verified

Biozenta Lifescience Private Limited is an Indian pharmaceutical exporter with a total trade value of $113.9K across 3 products in 1 therapeutic categories. Based on 12 verified export shipments from Indian Customs (DGFT) records, Biozenta Lifescience Private Limited is the #1 Indian exporter in 1 product including Daunorubicin. Top exports include Daunorubicin ($87.0K), Mercaptopurine ($23.6K), Mitoxantrone ($3.3K).

Biozenta Lifescience Private Limited — Export Portfolio & Destination Treemap

Biozenta Lifescience Private Limited pharmaceutical export portfolio — 3 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Biozenta Lifescience Private Limited? — Company Overview & Market Position

Biozenta Lifescience Private Limited, established on February 22, 2018, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company operates under the Corporate Identification Number (CIN) U74999MH2018PTC440022 and is registered with the Registrar of Companies (RoC) Mumbai. With an authorized capital of ₹1.00 crore and a paid-up capital of ₹60.00 lakh, Biozenta Lifescience has demonstrated significant growth since its inception. As of March 31, 2023, the company reported a revenue of $3.89 million USD, a net profit of $35,590 USD, and an EBITDA of $1.46 million USD.

The company's operations are managed by a team of directors, including Deep Narayan (Managing Director), Babita Saini, Abhishek Jain, Subodh Saini, Jainendra Kumar Sahu, and Sushil Kumar. As of January 9, 2026, Biozenta Lifescience employed approximately 55 professionals. The company's registered office is located at #7/54, Building No. 7, Anand Nagar Sahayog Cooperative Housing Society Ltd, Nehru Road, Mumbai, Maharashtra, 400055.

What Does Biozenta Lifescience Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Daunorubicin$87.0K

Product Portfolio — Top 3 by Export Value

Biozenta Lifescience Private Limited exports 3 pharmaceutical products across 1 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Daunorubicin	Advanced Oncology	$87.0K	6	12.6%	1
2	Mercaptopurine	Advanced Oncology	$23.6K	3	4.0%	5
3	Mitoxantrone	Advanced Oncology	$3.3K	3	0.2%	8

Biozenta Lifescience Private Limited exports 3 pharmaceutical products across 1 therapeutic categories with a total export value of $113.9K. The company is the #1 Indian exporter in 1 product: Daunorubicin. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Biozenta Lifescience Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Biozenta Lifescience operates a state-of-the-art manufacturing facility in Una, Himachal Pradesh, India. This plant is WHO-cGMP certified and EU GMP approvable, specializing in the production of oncology products, including liquid and lyophilized injections, tablets, and capsules, as well as general injectables such as liquid and lyophilized injections and pre-filled syringes. The facility is strategically located to cater to both domestic and international markets, ensuring compliance with global quality standards.

3Key Leadership

The leadership team at Biozenta Lifescience is spearheaded by Managing Director Deep Narayan, who has been instrumental in the company's growth and strategic direction since its inception. Other key executives include Babita Saini, Abhishek Jain, Subodh Saini, Jainendra Kumar Sahu, and Sushil Kumar, each contributing to the company's diverse operations and expansion efforts. Their collective expertise in pharmaceutical manufacturing, regulatory affairs, and international business development has been pivotal in establishing Biozenta Lifescience as a competitive player in the global pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Biozenta Lifescience Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Biozenta Lifescience has made significant strides in penetrating regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Una, Himachal Pradesh, is WHO-cGMP certified and EU GMP approvable, indicating adherence to international quality standards. Additionally, Biozenta has secured product registrations in over 30 countries across Asia, Africa, Europe, Latin America, and the GCC, with more than 180 international product registrations. These certifications and registrations facilitate market access and underscore the company's commitment to quality and regulatory compliance.

2Emerging Markets

Biozenta Lifescience has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's WHO-cGMP certified facility and EU GMP approvable status enable it to meet the stringent regulatory requirements of these regions. By obtaining product registrations in over 30 countries, Biozenta has enhanced its ability to participate in government tenders and supply to public health programs, thereby increasing its footprint in these emerging markets.

3Geographic Strategy

Biozenta Lifescience Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of March 28, 2026, Biozenta Lifescience has not publicly disclosed specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The company's focus on WHO-cGMP certification and EU GMP approvable status suggests a commitment to meeting international quality standards, which may facilitate future FDA approvals. However, without explicit information, a comprehensive assessment of Biozenta's FDA status cannot be provided.

2WHO & EU GMP

Biozenta Lifescience's manufacturing facility in Una, Himachal Pradesh, is WHO-cGMP certified and EU GMP approvable, indicating compliance with international quality standards. These certifications are crucial for market access in regulated regions and reflect the company's commitment to maintaining high manufacturing standards. The EU GMP approvable status further enhances Biozenta's credibility in the European market, positioning it favorably for future collaborations and market expansion.

3CDSCO & Indian Regulatory

Biozenta Lifescience Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the oncology pharmaceutical sector, Biozenta Lifescience faces competition from both domestic and international manufacturers. Key competitors include established Indian pharmaceutical companies with a strong presence in oncology products, as well as multinational corporations operating in the same therapeutic area. While specific market share data is not publicly available, Biozenta's focus on high-quality, affordable oncology medicines positions it as a competitive player in the market. The company's WHO-cGMP certified facility and EU GMP approvable status further enhance its competitive edge.

2Key Differentiators

Biozenta Lifescience's key differentiators include its commitment to innovation, quality, and global reach. The company's manufacturing facility in Una, Himachal Pradesh, is WHO-cGMP certified and EU GMP approvable, ensuring adherence to international quality standards. Additionally, Biozenta has secured product registrations in over 30 countries, with more than 180 international product registrations, reflecting its extensive global presence. These factors collectively contribute to Biozenta's competitive advantages in the pharmaceutical industry.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Biozenta Lifescience Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Biozenta Lifescience has demonstrated a strong track record in pharmaceutical manufacturing, with a focus on oncology and critical care products. The company's manufacturing facility in Una, Himachal Pradesh, is WHO-cGMP certified and EU GMP approvable, indicating adherence to international quality standards. While specific export volumes and consistency metrics are not publicly disclosed, the company's product registrations in over 30 countries and more than 180 international product registrations suggest a reliable and consistent export performance. These factors collectively indicate Biozenta's reliability as a pharmaceutical supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Biozenta Lifescience as a supplier:

WHO-cGMP Certification: Confirms compliance with World Health Organization

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Biozenta Lifescience Private Limited

How many pharmaceutical products does Biozenta Lifescience Private Limited export from India?

Biozenta Lifescience Private Limited exports 3 pharmaceutical products across 1 therapeutic categories. The top exports are Daunorubicin ($87.0K), Mercaptopurine ($23.6K), Mitoxantrone ($3.3K). Total export value is $113.9K.

What is Biozenta Lifescience Private Limited's total pharmaceutical export value?

Biozenta Lifescience Private Limited's total pharmaceutical export value is $113.9K, based on 12 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Biozenta Lifescience Private Limited the #1 Indian exporter?

Biozenta Lifescience Private Limited is the #1 Indian exporter in 1 products: Daunorubicin (12.6% market share).

What therapeutic categories does Biozenta Lifescience Private Limited cover?

Biozenta Lifescience Private Limited exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 3 products).

Get Full Biozenta Lifescience Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.